The New England journal of medicine
-
Letter Randomized Controlled Trial
Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.
-
Randomized Controlled Trial Multicenter Study
Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa.
The MORDOR I trial (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) showed that in Niger, mass administration of azithromycin twice a year for 2 years resulted in 18% lower postneonatal childhood mortality than administration of placebo. Whether this benefit could increase with each administration or wane owing to antibiotic resistance was unknown. ⋯ We found no evidence that the effect of mass administration of azithromycin on childhood mortality in Niger waned in the third year of treatment. Childhood mortality decreased when communities that had originally received placebo received azithromycin. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT02047981.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. ⋯ Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).